Related Experiment Video
Updated: Jun 2, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
RUNX1T1 is overexpressed in imatinib mesylate-resistant cells
Renata Binato1, Andre Mencalha, Luciana Pizzatti
1Instituto Nacional de Câncer (INCa), Divisão de Laboratórios do CEMO, Rio de Janeiro, RJ, Brazil. rbgomes@inca.gov.br.
Abstract:
The Philadelphia (Ph) chromosome, which occurs as a result of a translocation between chromosomes 9 and 22, generates a BCR-ABL fusion oncogene in leukaemia cells. The BCR-ABL fusion protein has constitutive tyrosine kinase activity. The development of imatinib mesylate (STI571, Gleevec®), a potent and selective BCR-ABL tyrosine kinase inhibitor, represents an important advance in cancer therapy. However, inherent mechanisms confer resistance to imatinib mesylate in some leukaemia patients. In order to identify the genes potentially related to these resistance mechanisms, we examined genes differentially expressed in BCR-ABL-positive cell lines resistant to imatinib mesylate. A comparison of global gene expression using the HG-U133 2.0 plus Gene Chip array was first performed. Twenty-three genes were shown to be overexpressed in an imatinib-resistant cell line. Among these, RUNX1T1 was shown to be overexpressed in another resistant cell line and in patients resistant to imatinib mesylate. This suggests that RUNX1T1 is a putative candidate for the further study of imatinib mesylate resistance.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle
Non-LTR Retrotransposons
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...

